Groowe Groowe / Newsroom / REGN
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

REGN News

Regeneron Pharmaceuticals Inc

Drug-Delivery Technology Market Report 2026

globenewswire.com
MRK ABBV SNY AZN NVS GSK TEVA REGN VRTX ALKS HALO

Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight

prnewswire.com
AMRX NVO AMGN REGN GSK SNY AZN PFE BMRA MRK

San Diego's Largest Community-Powered Cancer Research Fundraiser Returns: Curebound Cancer Challenge to Accelerate Cures

businesswire.com
JPM PFE DXCM ILMN REGN RMD

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

accessnewswire.com
NNVC GILD REGN

Form 8-K

sec.gov
REGN

Tumor Microenvironment Modulation Market to Hit USD 3.73 Billion by 2031 with a 7.4% CAGR - Key Trends and Insights

globenewswire.com
BMY MRK AZN PFE REGN GILD AMGN BE LLY IOVA NVS

Blood Cancer United Welcomes New Board Members & Philanthropy Leadership

prnewswire.com
VVV BIIB BMY GILD MRK PFE AMGN REGN JNJ ABBV LULU CGC CRON ACB TLRY SNDL CVS UNH CI CNC HCA THC AI NVDA MSFT GOOG IBM ORCL AMD INTC QCOM AMAT MU SMCI ADSK CBRE JLL SPG PLD EQIX AMT

DigiCert Introduces Quantum Central to Help Organizations Prepare for Post-Quantum Cryptography

globenewswire.com
MSFT GOOG AMZN IBM ORCL CSCO NVDA INTC AMD QCOM AMAT MU ADBE CRM ACN T VZ CMCSA NFLX DIS BA GD LMT RTX HON GE CAT JPM BAC WFC C GS MS AXP V MA PYPL KO PEP MCD SBUX COST WMT HD UNH JNJ PFE MRK ABBV BMY LLY GILD AMGN BIIB REGN VRTX GNTX CTAS PAYX ADP LRCX KLAC NXPI MRVL SNPS CDNS MCHP ON ADI TXN QGEN ILMN MDT SYK ISRG ALGN EW TMO DHR GOOGL AAPL META TSLA

Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair

businesswire.com
ULTA CRSP GILD PFE NVS REGN UCB LLY BIIB ARCL

Dupilumab Improves Outcomes for EoG in Phase 2 Clinical Trial

prnewswire.com
REGN SNY